Pneumonia Vaccine Industry Research Report 2025
Description
Summary
According to APO Research, the global Pneumonia Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Pneumonia Vaccine include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Zhifei Biologic, Walvax Biotechnology, Serum Institute of India Pvt. Ltd., Sanofi Pasteur and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pneumonia Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumonia Vaccine.
The report will help the Pneumonia Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Pneumonia Vaccine market size, estimations, and forecasts are provided in terms of sales volume (doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pneumonia Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Pneumonia Vaccine Segment by Company
Johnson & Johnson Merck & Co., Inc. Pfizer Inc. Glaxosmithkline Plc. Zhifei Biologic Walvax Biotechnology Serum Institute of India Pvt. Ltd. Sanofi Pasteur Royal (Wuxi) Bio-Pharmaceutical Emergent Biosolutions CSL Limited Astrazeneca Plc. Astellas Pharma Inc.Pneumonia Vaccine Segment by Type
Pneumococcal Conjugate Vaccine (PCV13) Pneumococcal Polysaccharide Vaccine (PPSV23) OtherPneumonia Vaccine Segment by Application
Sepsis Meningitis PneumoniaPneumonia Vaccine Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pneumonia Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pneumonia Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Pneumonia Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Pneumonia Vaccine include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Zhifei Biologic, Walvax Biotechnology, Serum Institute of India Pvt. Ltd., Sanofi Pasteur and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pneumonia Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumonia Vaccine.
The report will help the Pneumonia Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Pneumonia Vaccine market size, estimations, and forecasts are provided in terms of sales volume (doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pneumonia Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Pneumonia Vaccine Segment by Company
Johnson & Johnson Merck & Co., Inc. Pfizer Inc. Glaxosmithkline Plc. Zhifei Biologic Walvax Biotechnology Serum Institute of India Pvt. Ltd. Sanofi Pasteur Royal (Wuxi) Bio-Pharmaceutical Emergent Biosolutions CSL Limited Astrazeneca Plc. Astellas Pharma Inc.Pneumonia Vaccine Segment by Type
Pneumococcal Conjugate Vaccine (PCV13) Pneumococcal Polysaccharide Vaccine (PPSV23) OtherPneumonia Vaccine Segment by Application
Sepsis Meningitis PneumoniaPneumonia Vaccine Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pneumonia Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pneumonia Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
121 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pneumonia Vaccine Market Size (2020-2031)
- 2.2.2 Global Pneumonia Vaccine Sales (2020-2031)
- 2.2.3 Global Pneumonia Vaccine Market Average Price (2020-2031)
- 2.3 Pneumonia Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Pneumococcal Conjugate Vaccine (PCV13)
- 2.3.3 Pneumococcal Polysaccharide Vaccine (PPSV23)
- 2.3.4 Other
- 2.4 Pneumonia Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Sepsis
- 2.4.3 Meningitis
- 2.4.4 Pneumonia
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pneumonia Vaccine Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Pneumonia Vaccine Sales (doses) of Manufacturers (2020-2025)
- 3.3 Global Pneumonia Vaccine Revenue of Manufacturers (2020-2025)
- 3.4 Global Pneumonia Vaccine Average Price by Manufacturers (2020-2025)
- 3.5 Global Pneumonia Vaccine Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pneumonia Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Pneumonia Vaccine, Established Date
- 3.9 Global Pneumonia Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Johnson & Johnson Pneumonia Vaccine Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Merck & Co., Inc. Pneumonia Vaccine Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Pfizer Inc.
- 4.3.1 Pfizer Inc. Company Information
- 4.3.2 Pfizer Inc. Business Overview
- 4.3.3 Pfizer Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Pfizer Inc. Pneumonia Vaccine Product Portfolio
- 4.3.5 Pfizer Inc. Recent Developments
- 4.4 Glaxosmithkline Plc.
- 4.4.1 Glaxosmithkline Plc. Company Information
- 4.4.2 Glaxosmithkline Plc. Business Overview
- 4.4.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio
- 4.4.5 Glaxosmithkline Plc. Recent Developments
- 4.5 Zhifei Biologic
- 4.5.1 Zhifei Biologic Company Information
- 4.5.2 Zhifei Biologic Business Overview
- 4.5.3 Zhifei Biologic Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Zhifei Biologic Pneumonia Vaccine Product Portfolio
- 4.5.5 Zhifei Biologic Recent Developments
- 4.6 Walvax Biotechnology
- 4.6.1 Walvax Biotechnology Company Information
- 4.6.2 Walvax Biotechnology Business Overview
- 4.6.3 Walvax Biotechnology Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Walvax Biotechnology Pneumonia Vaccine Product Portfolio
- 4.6.5 Walvax Biotechnology Recent Developments
- 4.7 Serum Institute of India Pvt. Ltd.
- 4.7.1 Serum Institute of India Pvt. Ltd. Company Information
- 4.7.2 Serum Institute of India Pvt. Ltd. Business Overview
- 4.7.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio
- 4.7.5 Serum Institute of India Pvt. Ltd. Recent Developments
- 4.8 Sanofi Pasteur
- 4.8.1 Sanofi Pasteur Company Information
- 4.8.2 Sanofi Pasteur Business Overview
- 4.8.3 Sanofi Pasteur Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Sanofi Pasteur Pneumonia Vaccine Product Portfolio
- 4.8.5 Sanofi Pasteur Recent Developments
- 4.9 Royal (Wuxi) Bio-Pharmaceutical
- 4.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
- 4.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
- 4.9.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio
- 4.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
- 4.10 Emergent Biosolutions
- 4.10.1 Emergent Biosolutions Company Information
- 4.10.2 Emergent Biosolutions Business Overview
- 4.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Emergent Biosolutions Pneumonia Vaccine Product Portfolio
- 4.10.5 Emergent Biosolutions Recent Developments
- 4.11 CSL Limited
- 4.11.1 CSL Limited Company Information
- 4.11.2 CSL Limited Business Overview
- 4.11.3 CSL Limited Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 CSL Limited Pneumonia Vaccine Product Portfolio
- 4.11.5 CSL Limited Recent Developments
- 4.12 Astrazeneca Plc.
- 4.12.1 Astrazeneca Plc. Company Information
- 4.12.2 Astrazeneca Plc. Business Overview
- 4.12.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Astrazeneca Plc. Pneumonia Vaccine Product Portfolio
- 4.12.5 Astrazeneca Plc. Recent Developments
- 4.13 Astellas Pharma Inc.
- 4.13.1 Astellas Pharma Inc. Company Information
- 4.13.2 Astellas Pharma Inc. Business Overview
- 4.13.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio
- 4.13.5 Astellas Pharma Inc. Recent Developments
- 5 Global Pneumonia Vaccine Market Scenario by Region
- 5.1 Global Pneumonia Vaccine Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Pneumonia Vaccine Sales by Region: 2020-2031
- 5.2.1 Global Pneumonia Vaccine Sales by Region: 2020-2025
- 5.2.2 Global Pneumonia Vaccine Sales by Region: 2026-2031
- 5.3 Global Pneumonia Vaccine Revenue by Region: 2020-2031
- 5.3.1 Global Pneumonia Vaccine Revenue by Region: 2020-2025
- 5.3.2 Global Pneumonia Vaccine Revenue by Region: 2026-2031
- 5.4 North America Pneumonia Vaccine Market Facts & Figures by Country
- 5.4.1 North America Pneumonia Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Pneumonia Vaccine Sales by Country (2020-2031)
- 5.4.3 North America Pneumonia Vaccine Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pneumonia Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Pneumonia Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Pneumonia Vaccine Sales by Country (2020-2031)
- 5.5.3 Europe Pneumonia Vaccine Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pneumonia Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pneumonia Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Pneumonia Vaccine Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Pneumonia Vaccine Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pneumonia Vaccine Market Facts & Figures by Country
- 5.7.1 South America Pneumonia Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Pneumonia Vaccine Sales by Country (2020-2031)
- 5.7.3 South America Pneumonia Vaccine Revenue by Country (2020-2031)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pneumonia Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pneumonia Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Pneumonia Vaccine Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Pneumonia Vaccine Revenue by Country (2020-2031)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
- 6 Segment by Type
- 6.1 Global Pneumonia Vaccine Sales by Type (2020-2031)
- 6.1.1 Global Pneumonia Vaccine Sales by Type (2020-2031) & (doses)
- 6.1.2 Global Pneumonia Vaccine Sales Market Share by Type (2020-2031)
- 6.2 Global Pneumonia Vaccine Revenue by Type (2020-2031)
- 6.2.1 Global Pneumonia Vaccine Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Pneumonia Vaccine Revenue Market Share by Type (2020-2031)
- 6.3 Global Pneumonia Vaccine Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Pneumonia Vaccine Sales by Application (2020-2031)
- 7.1.1 Global Pneumonia Vaccine Sales by Application (2020-2031) & (doses)
- 7.1.2 Global Pneumonia Vaccine Sales Market Share by Application (2020-2031)
- 7.2 Global Pneumonia Vaccine Revenue by Application (2020-2031)
- 7.2.1 Global Pneumonia Vaccine Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Pneumonia Vaccine Revenue Market Share by Application (2020-2031)
- 7.3 Global Pneumonia Vaccine Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pneumonia Vaccine Value Chain Analysis
- 8.1.1 Pneumonia Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pneumonia Vaccine Production Mode & Process
- 8.2 Pneumonia Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pneumonia Vaccine Distributors
- 8.2.3 Pneumonia Vaccine Customers
- 9 Global Pneumonia Vaccine Analyzing Market Dynamics
- 9.1 Pneumonia Vaccine Industry Trends
- 9.2 Pneumonia Vaccine Industry Drivers
- 9.3 Pneumonia Vaccine Industry Opportunities and Challenges
- 9.4 Pneumonia Vaccine Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Pneumonia Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Pneumonia Vaccine Sales (doses) of Manufacturers (2020-2025)
- Table 7. Global Pneumonia Vaccine Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Pneumonia Vaccine Revenue of Manufacturers (2020-2025)
- Table 9. Global Pneumonia Vaccine Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Pneumonia Vaccine Average Price (US$/dose) of Manufacturers (2020-2025)
- Table 11. Global Pneumonia Vaccine Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Pneumonia Vaccine, Product Type & Application
- Table 14. Global Pneumonia Vaccine Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Pneumonia Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Johnson & Johnson Company Information
- Table 19. Johnson & Johnson Business Overview
- Table 20. Johnson & Johnson Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 21. Johnson & Johnson Pneumonia Vaccine Product Portfolio
- Table 22. Johnson & Johnson Recent Developments
- Table 23. Merck & Co., Inc. Company Information
- Table 24. Merck & Co., Inc. Business Overview
- Table 25. Merck & Co., Inc. Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 26. Merck & Co., Inc. Pneumonia Vaccine Product Portfolio
- Table 27. Merck & Co., Inc. Recent Developments
- Table 28. Pfizer Inc. Company Information
- Table 29. Pfizer Inc. Business Overview
- Table 30. Pfizer Inc. Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 31. Pfizer Inc. Pneumonia Vaccine Product Portfolio
- Table 32. Pfizer Inc. Recent Developments
- Table 33. Glaxosmithkline Plc. Company Information
- Table 34. Glaxosmithkline Plc. Business Overview
- Table 35. Glaxosmithkline Plc. Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 36. Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio
- Table 37. Glaxosmithkline Plc. Recent Developments
- Table 38. Zhifei Biologic Company Information
- Table 39. Zhifei Biologic Business Overview
- Table 40. Zhifei Biologic Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 41. Zhifei Biologic Pneumonia Vaccine Product Portfolio
- Table 42. Zhifei Biologic Recent Developments
- Table 43. Walvax Biotechnology Company Information
- Table 44. Walvax Biotechnology Business Overview
- Table 45. Walvax Biotechnology Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 46. Walvax Biotechnology Pneumonia Vaccine Product Portfolio
- Table 47. Walvax Biotechnology Recent Developments
- Table 48. Serum Institute of India Pvt. Ltd. Company Information
- Table 49. Serum Institute of India Pvt. Ltd. Business Overview
- Table 50. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 51. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio
- Table 52. Serum Institute of India Pvt. Ltd. Recent Developments
- Table 53. Sanofi Pasteur Company Information
- Table 54. Sanofi Pasteur Business Overview
- Table 55. Sanofi Pasteur Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 56. Sanofi Pasteur Pneumonia Vaccine Product Portfolio
- Table 57. Sanofi Pasteur Recent Developments
- Table 58. Royal (Wuxi) Bio-Pharmaceutical Company Information
- Table 59. Royal (Wuxi) Bio-Pharmaceutical Business Overview
- Table 60. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 61. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio
- Table 62. Royal (Wuxi) Bio-Pharmaceutical Recent Developments
- Table 63. Emergent Biosolutions Company Information
- Table 64. Emergent Biosolutions Business Overview
- Table 65. Emergent Biosolutions Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 66. Emergent Biosolutions Pneumonia Vaccine Product Portfolio
- Table 67. Emergent Biosolutions Recent Developments
- Table 68. CSL Limited Company Information
- Table 69. CSL Limited Business Overview
- Table 70. CSL Limited Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 71. CSL Limited Pneumonia Vaccine Product Portfolio
- Table 72. CSL Limited Recent Developments
- Table 73. Astrazeneca Plc. Company Information
- Table 74. Astrazeneca Plc. Business Overview
- Table 75. Astrazeneca Plc. Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 76. Astrazeneca Plc. Pneumonia Vaccine Product Portfolio
- Table 77. Astrazeneca Plc. Recent Developments
- Table 78. Astellas Pharma Inc. Company Information
- Table 79. Astellas Pharma Inc. Business Overview
- Table 80. Astellas Pharma Inc. Pneumonia Vaccine Sales (doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2020-2025)
- Table 81. Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio
- Table 82. Astellas Pharma Inc. Recent Developments
- Table 83. Global Pneumonia Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 84. Global Pneumonia Vaccine Sales by Region (2020-2025) & (doses)
- Table 85. Global Pneumonia Vaccine Sales Market Share by Region (2020-2025)
- Table 86. Global Pneumonia Vaccine Sales by Region (2026-2031) & (doses)
- Table 87. Global Pneumonia Vaccine Sales Market Share by Region (2026-2031)
- Table 88. Global Pneumonia Vaccine Revenue by Region (2020-2025) & (US$ Million)
- Table 89. Global Pneumonia Vaccine Revenue Market Share by Region (2020-2025)
- Table 90. Global Pneumonia Vaccine Revenue by Region (2026-2031) & (US$ Million)
- Table 91. Global Pneumonia Vaccine Revenue Market Share by Region (2026-2031)
- Table 92. North America Pneumonia Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 93. North America Pneumonia Vaccine Sales by Country (2020-2025) & (doses)
- Table 94. North America Pneumonia Vaccine Sales by Country (2026-2031) & (doses)
- Table 95. North America Pneumonia Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 96. North America Pneumonia Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 97. Europe Pneumonia Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 98. Europe Pneumonia Vaccine Sales by Country (2020-2025) & (doses)
- Table 99. Europe Pneumonia Vaccine Sales by Country (2026-2031) & (doses)
- Table 100. Europe Pneumonia Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 101. Europe Pneumonia Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 102. Asia Pacific Pneumonia Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 103. Asia Pacific Pneumonia Vaccine Sales by Country (2020-2025) & (doses)
- Table 104. Asia Pacific Pneumonia Vaccine Sales by Country (2026-2031) & (doses)
- Table 105. Asia Pacific Pneumonia Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 106. Asia Pacific Pneumonia Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 107. South America Pneumonia Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 108. South America Pneumonia Vaccine Sales by Country (2020-2025) & (doses)
- Table 109. South America Pneumonia Vaccine Sales by Country (2026-2031) & (doses)
- Table 110. South America Pneumonia Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 111. South America Pneumonia Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 112. Middle East and Africa Pneumonia Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 113. Middle East and Africa Pneumonia Vaccine Sales by Country (2020-2025) & (doses)
- Table 114. Middle East and Africa Pneumonia Vaccine Sales by Country (2026-2031) & (doses)
- Table 115. Middle East and Africa Pneumonia Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 116. Middle East and Africa Pneumonia Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 117. Global Pneumonia Vaccine Sales by Type (2020-2025) & (doses)
- Table 118. Global Pneumonia Vaccine Sales by Type (2026-2031) & (doses)
- Table 119. Global Pneumonia Vaccine Sales Market Share by Type (2020-2025)
- Table 120. Global Pneumonia Vaccine Sales Market Share by Type (2026-2031)
- Table 121. Global Pneumonia Vaccine Revenue by Type (2020-2025) & (US$ Million)
- Table 122. Global Pneumonia Vaccine Revenue by Type (2026-2031) & (US$ Million)
- Table 123. Global Pneumonia Vaccine Revenue Market Share by Type (2020-2025)
- Table 124. Global Pneumonia Vaccine Revenue Market Share by Type (2026-2031)
- Table 125. Global Pneumonia Vaccine Price by Type (2020-2025) & (US$/dose)
- Table 126. Global Pneumonia Vaccine Price by Type (2026-2031) & (US$/dose)
- Table 127. Global Pneumonia Vaccine Sales by Application (2020-2025) & (doses)
- Table 128. Global Pneumonia Vaccine Sales by Application (2026-2031) & (doses)
- Table 129. Global Pneumonia Vaccine Sales Market Share by Application (2020-2025)
- Table 130. Global Pneumonia Vaccine Sales Market Share by Application (2026-2031)
- Table 131. Global Pneumonia Vaccine Revenue by Application (2020-2025) & (US$ Million)
- Table 132. Global Pneumonia Vaccine Revenue by Application (2026-2031) & (US$ Million)
- Table 133. Global Pneumonia Vaccine Revenue Market Share by Application (2020-2025)
- Table 134. Global Pneumonia Vaccine Revenue Market Share by Application (2026-2031)
- Table 135. Global Pneumonia Vaccine Price by Application (2020-2025) & (US$/dose)
- Table 136. Global Pneumonia Vaccine Price by Application (2026-2031) & (US$/dose)
- Table 137. Key Raw Materials
- Table 138. Raw Materials Key Suppliers
- Table 139. Pneumonia Vaccine Distributors List
- Table 140. Pneumonia Vaccine Customers List
- Table 141. Pneumonia Vaccine Industry Trends
- Table 142. Pneumonia Vaccine Industry Drivers
- Table 143. Pneumonia Vaccine Industry Restraints
- Table 144. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Pneumonia Vaccine Product Image
- Figure 5. Global Pneumonia Vaccine Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Pneumonia Vaccine Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Pneumonia Vaccine Sales (2020-2031) & (doses)
- Figure 8. Global Pneumonia Vaccine Average Price (US$/dose) & (2020-2031)
- Figure 9. Pneumococcal Conjugate Vaccine (PCV13) Product Image
- Figure 10. Pneumococcal Polysaccharide Vaccine (PPSV23) Product Image
- Figure 11. Other Product Image
- Figure 12. Sepsis Product Image
- Figure 13. Meningitis Product Image
- Figure 14. Pneumonia Product Image
- Figure 15. Global Pneumonia Vaccine Revenue Share by Manufacturers in 2024
- Figure 16. Global Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters
- Figure 17. Global Top 5 and 10 Pneumonia Vaccine Players Market Share by Revenue in 2024
- Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 19. Global Pneumonia Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 20. Global Pneumonia Vaccine Sales by Region in 2024
- Figure 21. Global Pneumonia Vaccine Revenue by Region in 2024
- Figure 22. North America Pneumonia Vaccine Market Size by Country in 2024
- Figure 23. North America Pneumonia Vaccine Sales Market Share by Country (2020-2031)
- Figure 24. North America Pneumonia Vaccine Revenue Market Share by Country (2020-2031)
- Figure 25. United States Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 26. Canada Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 27. Mexico Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 28. Europe Pneumonia Vaccine Market Size by Country in 2024
- Figure 29. Europe Pneumonia Vaccine Sales Market Share by Country (2020-2031)
- Figure 30. Europe Pneumonia Vaccine Revenue Market Share by Country (2020-2031)
- Figure 31. Germany Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. France Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. U.K. Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Italy Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. Russia Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Spain Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Netherlands Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Switzerland Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Sweden Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 40. Poland Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 41. Asia Pacific Pneumonia Vaccine Market Size by Country in 2024
- Figure 42. Asia Pacific Pneumonia Vaccine Sales Market Share by Country (2020-2031)
- Figure 43. Asia Pacific Pneumonia Vaccine Revenue Market Share by Country (2020-2031)
- Figure 44. China Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. Japan Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. South Korea Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. India Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Australia Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Taiwan Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. Southeast Asia Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 51. Southeast Asia Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 52. South America Pneumonia Vaccine Market Size by Country in 2024
- Figure 53. South America Pneumonia Vaccine Sales Market Share by Country (2020-2031)
- Figure 54. South America Pneumonia Vaccine Revenue Market Share by Country (2020-2031)
- Figure 55. Brazil Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Argentina Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 57. Chile Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 58. Middle East and Africa Pneumonia Vaccine Market Size by Country in 2024
- Figure 59. Middle East and Africa Pneumonia Vaccine Sales Market Share by Country (2020-2031)
- Figure 60. Middle East and Africa Pneumonia Vaccine Revenue Market Share by Country (2020-2031)
- Figure 61. Egypt Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 62. South Africa Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 63. Israel Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 64. Türkiye Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 65. GCC Countries Pneumonia Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 66. Global Pneumonia Vaccine Sales Market Share by Type (2020-2031)
- Figure 67. Global Pneumonia Vaccine Revenue Market Share by Type (2020-2031)
- Figure 68. Global Pneumonia Vaccine Price (US$/dose) by Type (2020-2031)
- Figure 69. Global Pneumonia Vaccine Sales Market Share by Application (2020-2031)
- Figure 70. Global Pneumonia Vaccine Revenue Market Share by Application (2020-2031)
- Figure 71. Global Pneumonia Vaccine Price (US$/dose) by Application (2020-2031)
- Figure 72. Pneumonia Vaccine Value Chain
- Figure 73. Pneumonia Vaccine Production Mode & Process
- Figure 74. Direct Comparison with Distribution Share
- Figure 75. Distributors Profiles
- Figure 76. Pneumonia Vaccine Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
